Analyst picks & changes

Amgen Inc.

(AMGN)

Piper Jaffray analyst Barbara Hoffman said the newly published American Society of Clinical Oncology clinical practice guidelines on the use of colony stimulating factors will have a neutral impact overall on AMGN's

Neupogen

G-CSF.

The guidelines, which argue

Read the full 423 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE